# Ozempic and Longevity

In people with obesity, GLP-1 drugs like semaglutide show real organ protection: 20% fewer major heart events (SELECT) and 24% fewer major kidney events (FLOW), with a nominal 19% drop in all-cause death. But there is no proof yet that they extend lifespan, and no evidence of any longevity benefit at a normal weight. The known risks (muscle loss, gut side effects, rare serious events) still apply, so strength training and adequate protein are non-negotiable.

Semaglutide, tirzepatide, and the longevity question. Here is what the current evidence actually shows.

## On this page

- What are GLP-1 agonists?
- Is weight loss the same as living longer?
- What do the big GLP-1 trials actually show?
- What are the risks and side effects?
- How should you think about GLP-1 for longevity?

## FAQ

- Do GLP-1 drugs extend lifespan?
- What's the difference between Ozempic and Wegovy?
- Can I take GLP-1 just for longevity if I'm not overweight?
- What happens when I stop taking GLP-1?
- How important is strength training during GLP-1 use?

## Sources

- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2307563
- Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al.. (2023). Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2306963
- Perkovic V, Tuttle KR, Rossing P, et al.. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2403347
- Hathaway JT, Shah MP, Hathaway DB, et al.. (2024). Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmology. https://doi.org/10.1001/jamaophthalmol.2024.2296
- Aronne LJ, Sattar N, Horn DB, et al.. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. https://doi.org/10.1001/jama.2023.24945
- Sjöström L, Narbro K, Sjöström CD, et al.. (2007). Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects (SOS). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa066254
- The Look AHEAD Research Group. (2013). Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes (Look AHEAD). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa1212914
- Bundesministerium der Justiz. (2024). §34 SGB V — Ausgeschlossene Arznei-, Heil- und Hilfsmittel (Lifestyle-Arzneimittel). https://www.gesetze-im-internet.de/sgb_5/__34.html
- Cai CX, Hribar M, et al.. (2025). Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy (OHDSI multi-database analysis). JAMA Ophthalmology. https://doi.org/10.1001/jamaophthalmol.2024.6555
- Simonsen J, ..., Pottegård A (senior), et al.. (2025). NAION incidence in semaglutide-exposed cohorts: a Danish–Norwegian replication. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16316
- Loomba R, et al.. (2024). Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis (SYNERGY-NASH Phase 2). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2401943

_Full guide: https://longevity-switzerland.com/en/guide/glp1-longevity_

---

_Canonical: https://longevity-switzerland.com/en/guide/glp1-longevity · Part of Longevity Cities · Updated 2026-06-22_